Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 11;22(1):46–57. doi: 10.1093/neuonc/noz136

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

PMC Copyright notice

Fig. 1 — Correlation between NFAT2 expression and the clinic-pathologic features of gliomas. (A) NFAT2 mRNA expression is shown according to the histopathologic grades of REMBRANDT and TCGA gliomas. (B) Messenger RNA expression of NFAT2 is shown according to the molecular subtypes of REMBRANDT and TCGA GBMs. (C) NFAT2 mRNA expression is compared between primary and recurrent TCGA GBMs. (D) Prognostic significance of NFAT2 in REMBRANDT gliomas. (E–G) The prognostic significance of NFAT2 in MES GBMs was tested using the REMBRANDT database (E), Lee Y dataset (F), and Freije dataset (G). *P < 0.05, ***P < 0.001.